Chimeric Therapeutics Ltd News

Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4%

Chimeric Therapeutics (ASX:CHM) said the Phase 1/2 multi-center and first-in-human clinical trial for its CHM CDH17 CAR T cell therapy is now open for enrollment at SCRI Oncology Partners in Nashville

MT NewswiresMay 21 21:56 ET

Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial

Chimeric Therapeutics (ASX:CHM) secured ethics approval for the start of the multi-site Phase 1/2 clinical trial of CHM CDH17 cell therapy in patients with advanced gastrointestinal cancers, according

MT NewswiresMay 19 19:35 ET

Chimeric Therapeutics Reopens Enrollment in Phase 1B Cell Therapy Study

Chimeric Therapeutics (ASX:CHM) said that enrollment in the Phase 1B study of CHM CORE-NK cell therapy plus vactosertib has reopened, according to a Thursday filing with the Australian Securities Exch

MT NewswiresMay 15 20:55 ET

Chimeric Therapeutics Appoints COO; Shares Rise 4%

Chimeric Therapeutics (ASX:CHM) appointed Rebecca McQualter as its chief operating officer, the clinical stage cell therapy company said Thursday. McQualter has previously worked at companies such as

MT NewswiresMay 1 20:37 ET

Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20%

Chimeric Therapeutics (ASX:CHM) said Jennifer Chow has given notice of her resignation as the company's chief executive officer and managing director, effective May 24, according to a Wednesday filing

MT NewswiresApr 30 20:42 ET

Chimeric Therapeutics Obtains Patent Application Covering CORE-NK Technology; Shares Up 3%

Chimeric Therapeutics (ASX:CHM) said that the US Patent & Trademark Office has allowed for issuance of a patent application covering the CORE-NK platform technology for blood cancers and solid tumors,

MT NewswiresApr 4 20:08 ET

Chimeric Therapeutics Highlights Key Cell Therapy Targets in Treatment of Various Cancers

Chimeric Therapeutics (ASX: CHM) has reported strong progress for the 12 months to end December and highlighted key cell therapy targets for the coming year.

Small CapsMar 13 21:34 ET

Stocks of the Hour: PainChek, Chimeric Therapeutics, Torque Metals

To register for Friday's webinar click here.PainChek (ASX:PCK), developer of the world's first smart based pain assessment and monitoring application, has announced it has established a reseller agree

sharecafeMar 13 20:43 ET

Chimeric Therapeutics Treats First Patient in Phase 1B Leukemia Trial

Chimeric Therapeutics (ASX:CHM) treated the first patient in its phase 1b clinical trial investigating the use of the cell therapy CHM201 in combination with standard-of-care medication azacitidine an

MT NewswiresFeb 8 01:06 ET

Stocks of the Hour: QX Resources, Chimeric Therapeutics, Alliance Nickel

To register for Friday's webinar click here.QX Resources (ASX:QXR) announced that numerous brine aquifers were successfully intersected in the second hole of a two-hole diamond drill (DD) program over

sharecafeFeb 7 19:50 ET

Chimeric Therapeutics Sets New Horizons in Cell Therapy for Gastrointestinal and Brain Cancers

Clinical stage cell therapy company Chimeric Therapeutics (ASX: CHM) achieved significant success on a number of fronts during a highly-active quarter ending 31 December 2023.

Small CapsJan 31 02:35 ET

Chimeric Therapeutics to Raise AU$3.2 Milion Via Shortfall Placement

Chimeric Therapeutics (ASX:CHM) is seeking to raise about AU$3.2 million via the shortfall placement of an entitlement offer that raised about AU$4.5 million. The company will issue 114,317,500 ordina

MT NewswiresJan 18 01:38 ET

Chimeric Therapeutics Opens Phase 1B Leukemia Trial

Chimeric Therapeutics (ASX:CHM) opened its phase 1b trial evaluating the use of the cell therapy CHM 0201 in combination with standard-of-care therapies azacitidine and venetoclax in patients with rec

MT NewswiresJan 14 22:20 ET

Chimeric Therapeutics Begins Innovative Therapy Trial for Acute Myeloid Leukaemia

Australian cell therapy specialist Chimeric Therapeutics (ASX: CHM) has opened the door for enrolment in its international trial of a potential treatment for acute myeloid leukaemia (AML).

Small CapsJan 14 21:10 ET

Chimeric Therapeutics Receives AU$7 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%

Chimeric Therapeutics (ASX:CHM) received AU$7.4 million in rebates in the fiscal year ended June 30, 2023, as part of the Australian government's research and development tax incentive scheme, the cel

MT NewswiresJan 9 19:34 ET

Chimeric Therapeutics Secures AU$1 Million via Share Placement Deal

Chimeric Therapeutics (ASX:CHM) secured AU$1 million advanced payment from the Lind Global Fund II managed by New York-based investment firm the Lind Partners as part of a share placement deal first d

MT NewswiresJan 4 01:20 ET

Chimeric Therapeutics Shows Promise in Ovarian and Pancreatic Cancers

Chimeric Therapeutics (ASX:CHM), an Australian company specialising in cell therapy, has reported significant in vitro findings for its chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell thera

sharecafeNov 22, 2023 22:43 ET

Stocks of the Hour: Chimeric Therapeutics, Armada, Site Group International, Linius Technologies

To register for Friday's webinar click here.Chimeric Therapeutics (ASX:CHM) announced positive preclinical data for CHM 1301, the Company's off-the-shelf cell therapy. The results show up to 300% enha

sharecafeNov 22, 2023 20:03 ET

Chimeric Therapeutics Extends Closing Date of AU$10 Million Entitlement Offer

Chimeric Therapeutics (ASX:CHM) extended the closing date of its AU$10 million entitlement offer to Nov. 30. As a result of the extension, the issue date under the entitlement offer was moved to Dec.

MT NewswiresNov 15, 2023 01:21 ET

Chimeric Therapeutics Doses First Patient in Phase 1B Clinical Trial for Brain Cancer

Chimeric Therapeutics (ASX:CHM) said Thursday that the first patient in its Phase 1B clinical trial in recurrent and/or progressive glioblastoma multiforme received CHM 1101 CAR T cell treatment. CHM

MT NewswiresNov 1, 2023 22:00 ET